Maridea Wealth Management LLC bought a new position in Pfizer Inc. (NYSE:PFE - Free Report) in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The firm bought 27,281 shares of the biopharmaceutical company's stock, valued at approximately $724,000.
Other large investors have also recently made changes to their positions in the company. Nordea Investment Management AB grew its position in Pfizer by 36.1% in the 4th quarter. Nordea Investment Management AB now owns 4,071,700 shares of the biopharmaceutical company's stock valued at $108,002,000 after acquiring an additional 1,080,822 shares during the last quarter. Parsons Capital Management Inc. RI increased its stake in Pfizer by 118.7% in the 4th quarter. Parsons Capital Management Inc. RI now owns 294,764 shares of the biopharmaceutical company's stock worth $7,820,000 after buying an additional 159,984 shares during the period. NFJ Investment Group LLC lifted its holdings in Pfizer by 12.8% during the 3rd quarter. NFJ Investment Group LLC now owns 384,571 shares of the biopharmaceutical company's stock valued at $11,129,000 after buying an additional 43,719 shares in the last quarter. Copley Financial Group Inc. purchased a new stake in Pfizer in the 3rd quarter valued at about $577,000. Finally, Zacks Investment Management grew its stake in Pfizer by 10.9% in the third quarter. Zacks Investment Management now owns 2,389,138 shares of the biopharmaceutical company's stock worth $69,142,000 after purchasing an additional 235,243 shares in the last quarter. 68.36% of the stock is owned by hedge funds and other institutional investors.
Pfizer Stock Performance
Pfizer stock traded down $0.56 during trading hours on Tuesday, hitting $24.79. 17,244,001 shares of the stock traded hands, compared to its average volume of 44,812,039. The firm's 50 day moving average price is $26.05 and its 200-day moving average price is $26.88. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.00 and a quick ratio of 0.73. The stock has a market capitalization of $140.57 billion, a price-to-earnings ratio of 17.58, a P/E/G ratio of 0.64 and a beta of 0.61. Pfizer Inc. has a 1 year low of $24.48 and a 1 year high of $31.54.
Pfizer (NYSE:PFE - Get Free Report) last issued its quarterly earnings results on Tuesday, February 4th. The biopharmaceutical company reported $0.63 earnings per share for the quarter, topping the consensus estimate of $0.48 by $0.15. Pfizer had a net margin of 12.62% and a return on equity of 19.47%. The company had revenue of $17.76 billion for the quarter, compared to the consensus estimate of $17.26 billion. During the same quarter in the prior year, the company earned $0.10 EPS. Pfizer's quarterly revenue was up 24.7% on a year-over-year basis. As a group, equities analysts expect that Pfizer Inc. will post 2.95 EPS for the current fiscal year.
Analysts Set New Price Targets
Several analysts recently weighed in on the company. Guggenheim restated a "buy" rating on shares of Pfizer in a report on Tuesday, March 18th. Truist Financial lowered their target price on Pfizer from $36.00 to $32.00 and set a "buy" rating for the company in a report on Wednesday, December 18th. Hsbc Global Res upgraded Pfizer to a "strong-buy" rating in a report on Monday, March 10th. Citigroup decreased their price objective on Pfizer from $30.00 to $29.00 and set a "neutral" rating for the company in a research note on Tuesday, January 28th. Finally, Bank of America reiterated a "neutral" rating and issued a $29.00 target price on shares of Pfizer in a research note on Tuesday, December 10th. One equities research analyst has rated the stock with a sell rating, seven have issued a hold rating, six have given a buy rating and three have given a strong buy rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus price target of $31.92.
Read Our Latest Analysis on Pfizer
Insider Activity at Pfizer
In related news, Director Ronald E. Blaylock acquired 19,457 shares of Pfizer stock in a transaction on Thursday, February 13th. The stock was acquired at an average price of $25.65 per share, for a total transaction of $499,072.05. Following the purchase, the director now owns 27,707 shares of the company's stock, valued at approximately $710,684.55. This represents a 235.84 % increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. 0.06% of the stock is currently owned by insiders.
About Pfizer
(
Free Report)
Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.
Recommended Stories
Before you consider Pfizer, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Pfizer wasn't on the list.
While Pfizer currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
